Mechanism of PI3K activation and individualized anti-kinase therapy in gastric cancer

胃癌PI3K激活机制及个体化抗激酶治疗

• 批准号: 21790522
• 负责人: MUKOHARA Toru
• 金额: $ 2.75万
• 依托单位: Kobe University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21790522/
• 关键词: シグナル伝達; 個別化治療; 胃がん; PI3K

Foretinib, the novel muti-kinase inhibitor, appears effective against gastric cancer cells harboring not only MET but also FGFR2 amplification. There appears inter-RTK signaling networks with MET or FGFR2 at their core in at least part of gastric cancer cells, and the networks may contribute to efficient PI3K signaling. Foretinib exerts its inhibitory effects by blocking the networks.

Foretinib是一种新型多激酶抑制剂，对MET和FGFR 2扩增的胃癌细胞有效。在至少部分胃癌细胞中存在以MET或FGFR 2为核心的RTK间信号网络，该网络可能有助于有效的PI3K信号传导。Foretinib通过阻断网络发挥其抑制作用。

项目成果

Foretinib (GSK1363089) inhibits growth of gastric cancer cell lines through blockade of inter-receptor tyrosine kinases networks.

Foretinib (GSK1363089) 通过阻断受体间酪氨酸激酶网络来抑制胃癌细胞系的生长。

• 发表时间: 2010
• 作者: Mukohara T;Kataoka Y;Tomioka H;Kiyota N;Fujiwara Y;Yashiro M;Hirai M;Minami H.
• 通讯作者: Minami H.

Foretinib (GSK1363089) inhibits growth of gastric cancer cell lines through blockade of inter-receptor tyrosine kinase networks

Foretinib (GSK1363089) 通过阻断受体间酪氨酸激酶网络抑制胃癌细胞系的生长

• 发表时间: 2010
• 作者: Mukohara T;Kataoka Y;Tomioka H;Kiyota N;et al.
• 通讯作者: et al.

PI3K inhibitors overcome resistance to HER2-targeted agents caused by PIK3CA mutations in HER2-amplified breast cancer cell lines.

PI3K 抑制剂克服了 HER2 扩增乳腺癌细胞系中 PIK3CA 突变引起的对 HER2 靶向药物的耐药性。

• 发表时间: 2009
• 作者: Kataoka Y;Mukohara T;et al
• 通讯作者: et al